As we sharpen our focus on commercialization, we’re delighted to introduce you to four new members of Ontario Genomics’ Board of Directors to help us chart a new course and achieve our strategic goals.
Maureen Adamson, President of Fleming College and Interim President and CEO of Colleges Ontario, has more than 25 years of leadership experience in the post-secondary, health care, government and non-profit sectors.
Maureen has served as Ontario’s deputy minister of Tourism, Culture and Sport and deputy minister of the Status of Women. Other previous roles include president and CEO of the Michener Institute for Applied Health Sciences, CEO of Cystic Fibrosis Canada and vice-president of corporate services at Mohawk College.
Her volunteer work includes chairing the board of directors for Research Canada, serving as vice-chair and commissioner for the Toronto Transit Commission, and the inaugural chair of the Scarborough Health Network hospital in 2018 through Covid. She has been the inaugural chair of the Scarborough Health Research Institute since 2021.
Ian Ash is an entrepreneur and technology executive with over 25 years of experience scaling innovative technology companies.
As Co-Founder of Dig Insights, he helped build the company into a global organization and launched the high-growth SaaS platform, Upsiide, leading to a successful private equity exit.
Ian brings deep expertise in commercialization, strategic planning, and building the frameworks that turn innovative ideas into profitable enterprises. He is passionate about helping bridge the monetization gap for science and technology start-ups.
Pierre Meulien was most recently the Executive Director of the Innovative Medicines Initiative and oversaw its transition to the Innovative Health Initiative, a €2.4 billion cross-sector initiative in the health innovation ecosystem in Europe. He is now an independent consultant in biomedical R&I.
Previously, Dr Meulien was President and CEO of Genome Canada (2010-15) and was Chief Scientific Officer for Genome British Columbia. He has also served as founding CEO of the Dublin Molecular Medicine Centre and worked in the private sector with the French biotechnology company Transgene, and with Aventis Pasteur (now Sanofi Pasteur) as Director of Research at the Marcy l’Etoile (France) facility and then Senior Vice President for R&D at the Willowdale site (Ontario).
Greg Pope is Managing Partner of GDLP Advisors Inc., where he provides financial expertise and leadership to a variety of organizations in a number of different sectors.
With his deep financial background in multiple industries spanning four provinces, he provides clients with experienced financial leadership in areas such as raising capital, M&A, and bolstering the overall strength & effectiveness of the finance function within publicly traded and private organizations.
Greg has served in directorship roles in both corporate and charitable environments, bringing over 15 years of experience as Chief Financial Officer in the restaurant, retail, information technology and healthcare industries. Greg is currently a member of Memorial University’s Faculty of Business Advisory Board and has previously served on the boards of the National Arts Centre Foundation, CNIB, and certain corporate entities.
Dominique Tertigas is a PhD candidate at McMaster University in the Department of Biochemistry and Biomedical Sciences in the lab of Dr. Michael Surette. Dominique’s PhD project focuses on the gut microbiome in inflammatory bowel disease (IBD). Her work combines microbiology, genomics, and metagenomics to discover novel pathogens in IBD. Dominique has been awarded several scholarships, including the Canadian Graduate Scholarship (Master’s) and Ontario Graduate Scholarships, to support her research.
Dominique is a part of McMaster’s Michael G. DeGroote Institute for Infectious Disease Research and Farncombe Family Digestive Health Research Institute. As a trainee in these institutes, Dominique helps organize student-run conferences, plan trainee workshops, and mentor trainees in learning bioinformatics. Dominique has also applied her expertise in microbiome research to additional projects investigating the microbiome in the context of antibiotics, probiotic use, One Health, and more!
Dominique brings these experiences and training perspectives to Ontario Genomics’ Board as the student representative.
Ontario Genomics is also bidding farewell to a couple of retiring board members.
- Alan Winter (Former BC Innovation Commissioner) joined in October 2017 and was the Chair of the Governance, HR, and Nominating Committee and shared his extensive genomics and genome foundations expertise with the organization.
- Tom Corr (Former President and CEO, Ontario Centres of Excellence) brought his deep innovation expertise when he joined the Board in September 2018, and held several roles including Chair of the Finance & Audit Committee, former Vice Chair of the Board, member of the Private Sector Advisory Committee (PSAC).
Both Tom and Alan have made lasting contributions to the organization by playing a central role in launching the 2021 Strategic Plan, supporting the organization through leadership transitions, as well as helping guide Ontario Genomics through the COVID-19 pandemic, an era that also saw the inception of BioCreate, our best-in-class accelerator. We are thankful for their years of deep commitment to our board.